A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (“GPCR”) oral small molecule drug discovery powered by our proprietary Native Complex Platform®. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all FDA-approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023.
| Metric | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | 46M | 46M | - | - |
| Net Income | -49M | -49M | -72M | 567K |
| EPS | $-1.10 | $-1.10 | $-7.26 | $0.29 |
| Free Cash Flow | 110M | 110M | -70M | 36M |
| ROIC | -18.9% | -12.2% | -17.1% | 1.4% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.06 | 0.06 | 0.09 | -0.52 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -68M | -68M | -81M | 2.1M |
| Operating Margin | -148.6% | -148.6% | - | - |
| ROE | -12.8% | -12.2% | -17.1% | - |
| Shares Outstanding | 44M | 44M | 45M | 44M |
| Metric | 2023 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | N/A | 46M | 46M |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | 36M | 65M | 98M | 98M |
| SG&A | 9.7M | 17M | 29M | 29M |
| EBIT | 2.1M | -81M | -68M | -68M |
| Op. Margin | N/A | N/A | -148.6% | -148.6% |
| Net Income | 567K | -72M | -49M | -49M |
| Net Margin | N/A | N/A | -106.4% | -106.4% |
| Non-Recurring | 48M | 0 | 13M | 13M |
| Returns on Capital | ||||
| ROIC | 1.4% | -17.1% | -12.2% | -18.9% |
| ROE | N/A | -17.1% | -12.2% | -12.8% |
| ROA | 0.4% | -15.7% | -9.3% | -8.2% |
| Cash Flow | ||||
| Op. Cash Flow | 39M | -67M | 110M | 110M |
| Free Cash Flow | 36M | -70M | 110M | 110M |
| Owner Earnings | 36M | -72M | 100M | 100M |
| CapEx | 2.9M | 2.1M | 518K | 518K |
| Maint. CapEx | 848K | 1.4M | 1.6M | 1.6M |
| Growth CapEx | 2.0M | 702K | 0 | 0 |
| D&A | 848K | 1.4M | 1.6M | 1.6M |
| CapEx/OCF | N/A | N/A | N/A | 0.5% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 1.6M | 3.2M | 8.5M | 8.5M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | N/A | N/A | -367M | -97M |
| Cash & Equiv. | 88M | 238M | 121M | 121M |
| Long-Term Debt | N/A | N/A | N/A | 24M |
| Debt/Equity | -0.52 | 0.09 | 0.06 | 0.06 |
| Interest Coverage | N/A | N/A | N/A | N/A |
| Equity | -38M | 420M | 382M | 382M |
| Total Assets | 131M | 457M | 596M | 596M |
| Total Liabilities | 20M | 37M | 214M | 214M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -47M | -118M | -167M | -167M |
| Working Capital | 106M | 344M | 324M | 324M |
| Current Assets | 113M | 357M | 411M | 411M |
| Current Liabilities | 6.9M | 13M | 87M | 87M |
| Per Share Data | ||||
| EPS | 0.29 | -7.26 | -1.10 | -1.10 |
| Owner EPS | 0.82 | -1.60 | 2.25 | 2.25 |
| Book Value | -0.86 | 9.35 | 8.60 | 8.60 |
| Cash Flow/Share | 0.87 | -1.50 | 2.48 | -1.06 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 44.4M | 44.9M | 44.4M | 44.4M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -21.9 |
| P/FCF | N/A | N/A | N/A | 9.8 |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 2.7 | N/A | 2.8 |
| Price/Sales | N/A | N/A | N/A | 23.3 |
| FCF Yield | N/A | -6.2% | N/A | 10.2% |
| Market Cap | N/A | 1.1B | 0 | 1.1B |
| Avg. Price | N/A | 23.67 | 0.00 | 24.13 |
| Year-End Price | N/A | 25.33 | 0.00 | 24.13 |
Septerna, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
Septerna, Inc. trades at 1.8x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Cheap relative to its historical range.
Septerna, Inc. (SEPN) has a current P/E ratio of 1.8, compared to its historical median P/E of 15.0. The stock is currently considered Cheap based on its historical valuation range.
Septerna, Inc. (SEPN) has a 5-year average return on invested capital (ROIC) of -9.3%. This is below average and may indicate limited pricing power.
Septerna, Inc. (SEPN) has a market capitalization of $1.1B. It is classified as a small-cap stock.
Septerna, Inc. (SEPN) does not currently pay a regular dividend.
Based on historical P/E analysis, Septerna, Inc. (SEPN) appears cheap. The current P/E of 1.8 is 88% below its historical median of 15.0.
Septerna, Inc. (SEPN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Septerna, Inc. (SEPN) reported annual revenue of $46 million in its most recent fiscal year, based on SEC EDGAR filings.
Septerna, Inc. (SEPN) has a net profit margin of -106.4%. The company is currently unprofitable.
Septerna, Inc. (SEPN) generated $110 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Septerna, Inc. (SEPN) has a debt-to-equity ratio of 0.06. This indicates a conservatively financed balance sheet.
Septerna, Inc. (SEPN) reported earnings per share (EPS) of $-1.10 in its most recent fiscal year.
Septerna, Inc. (SEPN) has a return on equity (ROE) of -12.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Septerna, Inc. (SEPN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Septerna, Inc. (SEPN) has a book value per share of $8.60, based on its most recent annual SEC filing.